After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...

While the 2026 J.P. Morgan Healthcare Conference has thus far failed to yield any major M&A deals for the industry, Medtronic believes the time is ripe for buyouts. | While the 2026 J.P. Morgan ...

The twisting journey of Pretzel Therapeutics’ top brass appears to have come full circle, with the biotech subsuming the very ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

After a year of significant disruption at Novo Nordisk, the company's R&D chief has told Fierce Biotech that the deal-hungry ...

The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...

Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute (NHLBI) director, adding to the e | Gary Gibbons, ...

Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.

Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...